Oliver von Stein
Directeur Général chez Berlin Cures Holding AG
Profil
Oliver von Stein was the founder and had founded InDex Pharmaceuticals Holding AB in 2000, where he held the title of Chief Scientific Officer from 2009 to 2013.
He is currently the Chief Executive Officer at Berlin Cures Holding AG since 2023.
Dr. von Stein's former positions include Operations Director at Silence Therapeutics Plc from 2014 to 2015 and Project Leader at MediGene AG.
Dr. von Stein holds a doctorate degree from Karlsruher Institut für Technologie.
Postes actifs de Oliver von Stein
| Sociétés | Poste | Début |
|---|---|---|
Berlin Cures Holding AG
 Berlin Cures Holding AG BiotechnologyHealth Technology Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023. | Directeur Général | 15/06/2023 |
Anciens postes connus de Oliver von Stein
| Sociétés | Poste | Fin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Directeur des opérations | 01/08/2015 |
| MEDIGENE AG | Corporate Officer/Principal | - |
| FLERIE INVEST AB | Fondateur | - |
Formation de Oliver von Stein
| Karlsruher Institut für Technologie | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| FLERIE INVEST AB | Health Technology |
| MEDIGENE AG | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Entreprise privées | 1 |
|---|---|
Berlin Cures Holding AG
Berlin Cures Holding AG BiotechnologyHealth Technology Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023. | Health Technology |
